STING1 and cancer: Notably, non‐CDN STING agonists, such as 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA), dimeric amidobenzimidazole (diABZI), benzothiophene oxobutanoic acid (MSA‐2), and SR‐717, have demonstrated the capacity to elicit systemic antitumor immunity across various cancer types.